习近平总书记指出，外资企业是中国式现代化的重要参与者，是中国改革开放和创新创造的重要参与 者，是中国联通世界、融入经济全球化的重要参与者。北京，正是这片投资沃土上的璀璨明珠。2024 年，外资企业为北京市的进出口、工业增加值、税收和就业等方面均提供了强力支撑，为首都高质量发 展作出了重要贡献。当前，尽管面临一些挑战，但北京凭借其活跃的国际交往、集聚的创新资源、"两 区"政策叠加优势和一流的营商环境，完全有底气、有能力以更加自信开放的姿态，做好首都外资招引 工作。 来源：北京日报客户端 北京是包容共享的开放之城，为外资企业提供合作发展的绝佳平台。北京承担着重大主场外交和多边外 交活动职能，每年组织众多高规格外事活动，持续吸引全球目光。作为全球唯一的"双奥之城"，北京以 无与伦比的奥运盛会赢得了世界广泛赞誉。随着雁栖湖国际会都、第四使馆区等重点设施的完善，北京 的国际交往综合承载能力持续提升，城市国际化环境显著优化。近年来，北京着力打造服贸会、中关村 论坛、金融街论坛、北京文化论坛等高能级对外开放平台，精心策划组织"北京之夜"等品牌活动，推动 一批标志性外资项目落地。跨国公司地区总部与外资研发中心持续集聚，入围《 ...

Core Insights - In 2024, the trade value between China and ASEAN reached 6.99 trillion RMB, marking a 9.0% year-on-year increase and accounting for 15.9% of China's total foreign trade [1] - The ASEAN Economic Promotion Association, established in August 2024, aims to enhance cooperation across various sectors including trade, technology, education, culture, and tourism [1][3] - The association has built a robust cooperation network with institutions like the ASEAN Secretariat and China Council for the Promotion of International Trade, facilitating a three-dimensional linkage among government, enterprises, and think tanks [1] Trade and Economic Cooperation - China and ASEAN have been each other's largest trading partners for five consecutive years, with trade volume increasing 17 times since 2002, reaching 982.3 billion USD in 2024 [1][3] - The association has established a high-level exchange platform and a regular communication mechanism with multiple provinces in China, promoting various projects in the ASEAN region [3] Future Cooperation Plans - The ASEAN Economic Promotion Association plans to enhance cooperation with central enterprises by establishing efficient matching platforms, providing think tank support, addressing market access issues, and promoting standard recognition in infrastructure and digital sectors [4] - The year 2025 is highlighted as a critical year for the implementation of the upgraded China-ASEAN Free Trade Area 3.0 [4] Community Development Projects - The association is implementing "small but beautiful" livelihood projects, such as a cross-border logistics hub in Cambodia and agricultural technology cooperation in Vietnam, which enhance local efficiency and productivity [5] - These projects reflect the core philosophy of "development for the people" and signify the extension of cooperation from economic to social welfare areas [5]

Fixed Income Research - In October, the issuance scale of credit bonds decreased slightly, with corporate bonds and medium-term notes increasing, while company bonds, short-term financing bonds, and targeted tools saw a decrease in issuance [3] - The overall credit bond yield declined, but the monthly average showed a mixed trend compared to September, with most credit spreads narrowing [3] - The market is expected to continue a downward trend in yields, with a cautious approach recommended for high-priced bonds, while focusing on the value of individual bonds [3][4] Fund Research - The total scale of public funds exceeded 36 trillion yuan, with a recent draft for performance comparison benchmarks released by the CSRC [5] - In the week from October 27 to October 31, the average return of equity funds was 0.20%, with a positive return ratio of 57.93% [6] - The ETF market saw a net inflow of 238.35 billion yuan, with significant inflows into stock ETFs [6][7] Financial Engineering Research - The A-share market saw most major indices decline in October, with the margin balance continuing to rise, reaching 24,784.70 billion yuan by the end of the month [8][9] - The financing balance increased by 900.17 billion yuan, while the average daily trading volume in the ETF market was 5,559.23 billion yuan [9][10] Industry Research - The pharmaceutical and biotechnology sector is seeing positive developments, with the recent ESMO conference showcasing advancements in Chinese innovative drugs [11] - The steel industry showed significant improvement in performance, with a net profit of 218.53 billion yuan in the first three quarters of 2025, compared to losses in the previous year [14][15] - The non-ferrous metals sector also performed well, with a revenue growth of 9.30% and a net profit increase of 41.55% in the first three quarters of 2025 [16][19]

Core Points - The 8th China International Import Expo (CIIE) has set a new record with over 4,100 foreign enterprises participating and an exhibition area exceeding 430,000 square meters, showcasing global products and innovations [2][5] - The event has become a significant platform for international trade, with cumulative intended transaction amounts exceeding $500 billion over the first seven expos [3][4] - Major companies like New Zealand's Fonterra and Schneider Electric have reported substantial growth in sales and market presence in China due to their participation in CIIE [3][4] Group 1: Event Overview - The CIIE, initiated in 2018, is the world's first national-level expo focused on imports, attracting participants from 155 countries and regions [2] - This year's expo features over 3,000 new products, technologies, and services, reinforcing China's role as a major global market [6][7] Group 2: Company Highlights - Fonterra's sales of fresh milk in China have increased over 20 times since their first participation, with weekly sales rising from 3,000 to 80,000 bottles [3] - Schneider Electric showcased innovative products and emphasized its commitment to investing in China, highlighting the "CIIE effect" that has led to increased market penetration [4] - Alcon, focusing on eye health, presented over ten innovative products at the expo, marking its 30th anniversary in the Chinese market [5] Group 3: International Participation - The expo has attracted participation from various countries, with six nations serving as guest countries this year, including Nigeria and Sweden, which are participating for the first time [8] - Norway's seafood exports to China have surged, with a notable increase of approximately 36,000 tons, or 116%, compared to the previous year [7]

Core Insights - The China International Import Expo (CIIE) showcases innovative products across various sectors, including healthcare and automotive, with a record participation of 155 countries and over 4,108 foreign enterprises [1][2] Group 1: Product Highlights - The expo features groundbreaking medical products such as the needle-free intravenous catheter by BD Medical, which reduces the risk of needle-stick injuries and enhances safety for healthcare workers [2] - Fosun Pharma presents the Marie vertical particle therapy system, a revolutionary approach in cancer treatment that offers a cost-effective and space-saving alternative to traditional systems [2] - Tesla's Cybercab, an autonomous electric vehicle, makes its Asia-Pacific debut, utilizing a vision processing system and neural network for self-driving capabilities without expensive hardware [3] Group 2: Market Entry and Transformation - The CIIE serves as a platform for foreign companies to accelerate their entry into the Chinese market, with BD Medical reporting that nearly 95% of its showcased products have transitioned into commercial products [4] - Fosun Pharma has leveraged the expo's influence to introduce several advanced technologies and innovative medical products into China, enhancing the country's healthcare system [4] Group 3: Investment Opportunities - The expo not only facilitates product entry but also attracts exhibitors to become investors in China, as highlighted by BD Medical's plans to establish a new innovation center in Tianjin [5][6] - Companies like Tutti Pharmaceuticals have successfully entered the Chinese market through the expo and are now considering local manufacturing due to favorable conditions for research and development [6]

Group 1 - The Guangdong-Hong Kong-Macao Greater Bay Area Global Investment Conference was held in Guangzhou, showcasing the region's economic vitality and investment potential, aimed at attracting global enterprises [1] - The conference emphasized the advantages of a complete industrial chain, precise policy support, and regional collaboration, which injects momentum into industrial upgrades and reinforces the area's status as a global investment destination [1] Group 2 - Hong Kong ranked fourth in the 2025 World Digital Competitiveness Ranking, improving three places from the previous year, with strong performances in technology and knowledge [2] - The Hong Kong government has been actively enhancing its innovation and technology sector, establishing three major innovation parks and five research institutions to foster development and cultivate new productivity [2] Group 3 - Shenzhen is set to add five new "face recognition" smart customs ports, enhancing the existing smart passage at Shenzhen Bay, which will stimulate foreign trade and cross-border consumption [3] - This initiative is expected to inject continuous momentum into industrial collaboration and high-level openness in the Greater Bay Area, strengthening regional economic competitiveness [3] Group 4 - The 138th Canton Fair concluded with over 310,000 overseas buyers attending, marking a historical high [4] - The fair's success is attributed to the empowerment of new productivity and the advantages of a complete industrial chain, transforming "traffic" into trade momentum and reinforcing China's position as a preferred global trade destination [4] Group 5 - The Shenzhen Composite Index closed at 13,175.22 points, down 1.71% on November 4 [5] Group 6 - The top gainers in the Shenzhen market included Zhongneng Electric at 7.67 yuan with a 20.03% increase, and Zhaobiao Co. at 15.34 yuan also with a 20.03% increase [6] - The biggest losers included Changshan Pharmaceutical at 55.84 yuan with a 20.00% decrease, and Tonghe Technology at 29.26 yuan with a 15.07% decrease [6]

Core Insights - The company emphasizes technology innovation as its core driving force, focusing on multiple therapeutic areas including anti-infection and digestive systems [2] - The company adopts a strategy that combines generic and innovative drug development, primarily focusing on generics while advancing research in raw material drugs, innovative drugs, high-end formulations, and licorice series products [2] - In the medical device sector, the company covers a full range of distribution activities including import and export trade, direct sales, distribution, delivery, SPD, and retail, while continuously extending its service chain [2] - The company is committed to transforming and upgrading its business, accelerating the application of high-tech achievements, and actively extending upstream into the high-end of the industry chain [2]

Core Insights - China National Pharmaceutical Group Corporation officially launched a human resources management information system upgrade project in Beijing on October 31 [1] Group 1 - The project aims to enhance the efficiency and effectiveness of human resources management within the company [1]

Core Points - The establishment of the China (Xinjiang) Pilot Free Trade Zone on November 1, 2023, marks a significant development in the region, covering Urumqi, Kashgar, and Horgos, and aims to enhance trade and economic activities [2] - Since its establishment, Xinjiang's import and export trade volume has grown at an annual rate of 20% to 30%, consistently ranking among the top in the country [2] Group 1: Development Opportunities - The Horgos area has implemented a "three-in-one" joint review mechanism for pharmaceutical companies, reducing the approval process from two months to less than ten days, saving over one million yuan in costs [3][4] - In the first eight months of this year, 6,663 new enterprises were established in the region, a year-on-year increase of 10%, contributing to one-third of the new foreign-funded enterprises in Xinjiang [4] Group 2: Trade and Logistics - The Horgos port has seen a significant increase in efficiency, with an 80% improvement in overall customs clearance efficiency due to the introduction of a rapid customs clearance model [5] - In the first eight months of this year, Xinjiang's total foreign trade import and export value reached 356.31 billion yuan, a year-on-year increase of 25.4% [5] Group 3: Institutional Innovation - The Xinjiang Free Trade Zone has introduced 54 support policies and delegated 45 economic and social management powers to the regional level, promoting institutional innovation [7] - The establishment of the "two countries, double parks" model in the Kashgar Economic Development Zone aims to enhance cross-border logistics efficiency by 50% [6]

Core Viewpoint - *ST Suwu is facing significant challenges, including a sharp decline in revenue and net profit, alongside multiple delisting risks, particularly related to the arbitration case concerning the exclusive agency rights for the AestheFill product. Financial Performance - In Q3 2025, *ST Suwu reported a revenue decline of 63.93% year-on-year to 148 million yuan, with a net profit attributable to shareholders of approximately -43.05 million yuan, a drastic decrease of 308.72% compared to the same period last year [1][3] - For the first three quarters, the company's revenue fell by 38.85% to 784 million yuan, and the net profit decreased by 294.03% to -87.47 million yuan, primarily due to significant impairment provisions for trade receivables [4][5] - The pharmaceutical business generated a total revenue of 468 million yuan, down 55.79% year-on-year, while the medical aesthetics sector achieved a revenue of 304 million yuan, up 52.78% [4] Business Operations - The decline in revenue is attributed to a significant drop in income from pharmaceutical and medical aesthetics businesses, with the company admitting it is currently unable to continue selling AestheFill products due to ongoing arbitration [1][5] - AestheFill, a key product for *ST Suwu, was launched in 2024 and contributed significantly to the company's revenue, accounting for 35.55% of total revenue in Q1 2024 [5][6] Legal and Regulatory Issues - *ST Suwu is under scrutiny for alleged information disclosure violations, having received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation [7] - The company has been found to have inflated revenue by approximately 1.771 billion yuan from 2020 to 2023 through non-commercial trade activities, leading to multiple delisting risks [8][9] - The company has faced a series of legal challenges, including a criminal case against its subsidiary for tax fraud, which further complicates its financial situation [9]